Recombinant vWF Concentrate and ECMO

计划入组 12 人 · 首次发布于 2023 年 11 月 7 日

Pharmacokinetics of Oral CK-1827452 in Patients With Stable Heart Failure

计划入组 35 人 · 首次发布于 2009 年 7 月 17 日

INdividualized ITI Based on Fviii(ATE) Protection by VWF

计划入组 1 人 · 首次发布于 2017 年 7 月 2 日

HMB-VWF

Factor VIII/von Willebrand factor (Bio Products Laboratory)

CK-089

Domain Therapeutics SA

France

CEE-KAY SUPPLY, INC.

United States

IBM CDR (CAD Hedged)

Hemab Therapeutics Files for NASDAQ IPO to Advance Bleeding Disorder Therapies

Hemab Therapeutics Unveils HMB-002 Proof-of-Mechanism Data in VWD and Announces Novel Antifibrinolytic HMB-003 at ISTH 2026

Cytokinetics Initiates Phase 2 Trial of CK-586 for Heart Failure with Preserved Ejection Fraction